SRC inhibitor saracatinib enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

被引：0
|
作者：
Lu, Fei-Teng [1 ]
Luo, Fan [1 ]
Qiu, Miao-Zhen [1 ]
Cao, Jia-Xin [1 ]
Luo, Qiu-Yun [1 ]
Yang, Da-Jun [2 ]
Zhao, Hong-Yun [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ascentage Pharma Suzhou Co Ltd, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6094
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [2] Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
    Luo, Fan
    Luo, Min
    Rong, Qi-Xiang
    Zhang, Hong
    Chen, Zhen
    Wang, Fang
    Zhao, Hong-Yun
    Fu, Li-Wu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [3] Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
    Li, Lijun
    Pu, Haihong
    Zhang, Xiaoxin
    Guo, Xiaotian
    Li, Guangrui
    Zhang, Minghui
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 209
  • [4] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [5] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    LUNG CANCER, 2016, 99 : 79 - 87
  • [6] Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
    Zhang, Binbin
    Liu, Yi
    Zhou, Sijing
    Jiang, Huihui
    Zhu, Ke
    Wang, Ran
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [7] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
    Gonzalez-Velez, Abel
    Pino-Villareal, Luis E.
    Barrera-Barinas, Alexander
    Castillo-Niuman, Andrea
    Tolosa-Perez, Erica N.
    Castelblanco, Diana, I
    Pinzon-Florez, Carlos E.
    Yomayusa, Nancy
    GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
  • [8] PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges
    Meng, Xiangjiao
    Liu, Yanli
    Zhang, Jianjun
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    CANCER LETTERS, 2017, 405 : 29 - 37
  • [9] Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
    Huang, Mu-Yang
    Jiang, Xiao-Ming
    Wang, Bing-Lin
    Sun, Yang
    Lu, Jin-Jian
    PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [10] Research progression of PD-1/PD-L1 in non-small cell lung cancer
    Xing Liu
    Xiaodong Xie
    Oncology and Translational Medicine, 2017, 3 (03) : 111 - 115
12345